"Adrenocortical Carcinoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.
| Descriptor ID |
D018268
|
| MeSH Number(s) |
C04.557.470.200.025.152 C04.588.322.078.265.750 C19.053.098.265.750 C19.053.347.500.750 C19.344.078.265.750
|
| Concept/Terms |
Adrenocortical Carcinoma- Adrenocortical Carcinoma
- Adrenocortical Carcinomas
- Carcinomas, Adrenocortical
- Carcinoma, Adrenocortical
- Carcinoma, Adrenal Cortical
- Adrenal Cortical Carcinoma
- Adrenal Cortical Carcinomas
- Carcinomas, Adrenal Cortical
|
Below are MeSH descriptors whose meaning is more general than "Adrenocortical Carcinoma".
Below are MeSH descriptors whose meaning is more specific than "Adrenocortical Carcinoma".
This graph shows the total number of publications written about "Adrenocortical Carcinoma" by people in this website by year, and whether "Adrenocortical Carcinoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adrenocortical Carcinoma" by people in Profiles.
-
Predictors of Survival in Adrenocortical Carcinoma: An Analysis From the National Cancer Database. J Clin Endocrinol Metab. 2018 09 01; 103(9):3566-3573.
-
PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target. Surgery. 2013 Dec; 154(6):1405-16; discussion 1416.
-
Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma. Endocr Pract. 2010 May-Jun; 16(3):441-5.
-
Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol Cancer Ther. 2008 Feb; 7(2):425-31.